Quarterly Result15 May 2026, 06:51 pm
Aarti Drugs Approves FY26 Financial Results, Auditor Re-appointments
AI Summary
Aarti Drugs Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board also approved the re-appointment of M/s GMVP & Associates LLP as Cost Auditor for FY 2026-27 and M/s Raman S. Shah & Co. as Internal Auditor for three years starting April 1, 2026. Additionally, the Risk Management Committee was reconstituted with the inclusion of Shri Narendra J. Salvi as a member.
Key Highlights
- Audited standalone and consolidated financial results for FY26 approved.
- M/s GMVP & Associates LLP re-appointed as Cost Auditor for FY27.
- M/s Raman S. Shah & Co. re-appointed as Internal Auditor for 3 years.
- Risk Management Committee reconstituted with Shri Narendra J. Salvi as member.
Price Impact
More from AARTIDRUGS